tbuckley/cabot-search huggingface dataset:
Lung cancer immunochemotherapy: Codelivery of EGFR tki and PTX via an immunostimulatory dual functional nanocarrier.
Authors: Dingwei Diao, Kaican Cai, Xiguang Liu, Jianjun Yang
Journal: Journal of Clinical Oncology (2020)

e15177 Background: Immuno-target therapy combines a target therapy agent with an immune modulating agent and represents an attractive approach to improve cancer therapy.However, the success of it is hampered by the lack of a strategy to effectively co deliver the two therapeutics to the tumours.Here we report an improved dual functional nanocarrier (PEG5k-Fmoc-NLG2) to load Gefitinib for improved cancer Immuno target therapy.PEG5K-Fmoc-NLG2 is a prodrug that can inhibited IDO enzyme activity in vitro,while IDO1 inhibition reversed T cell suppression mediated by IDO expressing mouse cancer cells. Methods: Gefitinib loaded in carrier was prepared via a film hydrationmethod,the physicochemical properties of micelles was determined by TEM and particle size test.The cytotoxicity of the drug was detected by MTT assay. 3LL lung cancer was inoculated in mice and different drugs was injected through the tail vein to compare the anti tumor effect of drug loading micells with existing targeted drug gefitinib and CTLA4 antibody; tumor tissue proteins were extracted to clarify changes in pEGFR expressionexpression; flow cytometry will be finished to observe tumor immune microenvironment changes. Results: 1. Gefitinib loaded micelle maintain the similar size with blank PEG5k-fmoc-NLG2 micelles that is around 20nm.The drug-loaded micelles produced uniformed size and morphology. which further confirmed the size of micelles was around 20nm. 2. PTX and Gefitinib loaded in PEG5k-fmoc-NLG2 exhibited significantly enhanced tumor cell killing effect than the free drug on both A549 and 3LL cell lines. 3. The antitumor efficacy of different drugs loaded in the carrier were tested in a murine lung cancer model (3LL). All treatment showed significant better antitumor activity compared to the control group, Gefitinib/PEG5k-Fmoc-NLG2 plus CTLA4 antibody exhibited the best antitumor effect. Antitumor activity of gefitinib loaded in carrier was comparable with free gefitinib alone. 4. With various treatments the expression of p-EGFR protein level varied. Basically, compare with free gefitinib alone, the carrier loaded gefitinib was more effective in the inhibition of EGFR phosphorylation. Conclusions: We have shown that targeted delivery of PTX and Gefitinib via a immunostimulatory nanocarrier effectively improved drugs antitumor activity. More study about tumor immune microenvironment are required. Such strategy can be employed in novel therapy combining chemotherapy drugs and immunemodulating agents such as PD-1 and CTLA4.
Determinants of second pregnancy among pregnant women: a hospitalbased cross-sectional survey in China
Authors: 徐祥龙, 左寒晓, 史祖民, 饶运双, 王炼炼, 曾缓, 张磊, Sharma Manoj, Reis Cesar, 赵勇, 全艺博, 刘登远, 张张一, 林倩怡, 吴婷婷, 李婷婷, 邹茂
Journal: BMJ (2017)

目的
探索中国孕妇生育二胎的影响因素及潜在原因。


设计
本研究为基于医院的横断面调查。


地点
中国5个省的16家医院。


样本
2015年6月至8月，通过访谈式问卷调查法调查2 345名年龄≥18岁的孕妇。


主要结局指标
孕妇胎次(初胎孕妇或二胎孕妇)和生育二胎的原因。


结果
此研究共包含1 755名(74.8%)初胎孕妇以及590名(25.2%)二胎孕妇。二胎孕妇孕育二胎最常见的原因包括 为了第一个孩子好 (26.1%)、 喜欢孩子 (25.8%)、 顺应二胎政策 (11.5%)、 担心失独 (7.5%)以及 父母的建议 (7.5%)。低等教育水平[现患比(PR)1.96；95%可信区间（CI）1.62~2.36]和中等教育水平(PR 1.97；95%CI 1.65~2.36)的孕妇相对受过高等教育的孕妇更可能生育二胎。其中，由于 二胎政策 的影响，中等教育水平的妇女生育二胎的人数是低等教育水平的3倍。家庭人均月收入水平与二胎生育意愿呈负相关，但是失业的受调查者(PR 0.79；95%CI 0.66~0.95)比非失业者生育二胎的可能性更小。


结论
研究人群中四分之一的孕妇为二胎孕妇。 为第一个孩子好 及 喜爱孩子 是促使受调查者生育二胎的主要原因。低社会经济地位和二胎生育意愿呈正相关。新出台的二胎政策将会对中国的人口结构产生影响。
Plasma homocysteine, folic acid and vitamin B12 levels in patients with colon adenomatous polyps
Authors: Guang Li
Journal: BMJ (2013)

Plasma levels of homocysteine (Hcy), folic acid (FA) and Vitamin B12 (VB12) were measured in 120 patients of colon adenomatous polyps and 40 healthy subjects. Plasma Hcy levels in colon adenomatous polyps patients were significantly higher than those in controls[(14.24 ± 0.52) μmol/L vs.(10.93±0.81) μmol/L, P=0.0014)], while plasma FA levels in polyps patients were lower than those in controls [(6.26±0.27) μg/L vs.(10.74±0.85) μg/L, P<0.0001]. There was no difference in plasma VB12 levels between two groups(P=0.7100). The plasma Hcy levels in patients with multiple colon polyps were higher than those with single colon polyps(P=0.0092), while the plasma FA levels demonstrated contrary results (P=0.0047). With the pathological type progression, the plasma Hcy levels were gradually raised, and FA levels gradually decreased. Plasma levels of FA, Hcy and VB12 were not correlated with the location and distribution of polyps. These results suggest that plasma FA and Hcy levels may be related to disease progress in patients with colon adenomatous polyps.


Key words: 
Adenomatous polyposis Coli; Homocysteine
A basket trial of trastuzumab deruxtecan, a HER2-targeted antibody-drug conjugate, for HER2-amplified solid tumors identified by circulating tumor DNA analysis (HERALD trial).
Authors: Masataka Yagisawa, Yoshiaki Nakamura, Takayuki Yoshino, Yoshito Komatsu, Shigenori Kadowaki, Kei Muro, Yu Sunakawa, Taroh Satoh, Tomohiro Nishina, Taito Esaki, Satoshi Fujii, Hiromi Ono, Daiki Tomita, Noriko Fujishiro, Nami Hirano, Nozomu Fuse, Akihiro Sato, Gakuto Ogawa, Shogo Nomura, Hiroya Taniguchi
Journal: Journal of Clinical Oncology (2020)

TPS3650 Background: Trastuzumab deruxtecan, a new HER2-targeting antibody-drug conjugate, has been approved for unresectable or metastatic HER2-positive breast cancer by the Food and Drug Administration. In a phase I/II trial, trastuzumab deruxtecan showed a manageable safety profile and antitumor activity in HER2-positive various cancer types. In addition, a tissue-based HER2 test occasionally cannot identify accurate HER2 status due to spatial and temporal intratumoral heterogeneity, leading to potentially missing an opportunity for responders to receive benefit from anti-HER2-targeted therapy. Circulating tumor DNA (ctDNA) analysis can detect comprehensive somatic genome alterations by assessment of spatial and temporal intratumoral heterogeneity with minimal invasiveness. Methods: We designed an investigator-initiated multicenter phase II basket trial to evaluate efficacy and safety of trastuzumab deruxtecan in advanced solid tumor malignancies with HER2 amplification identified by Guardant360, a 74-gene sequencing ctDNA panel, as a part of the Nationwide Cancer Genome Screening Project (GOZILA study, UMIN000029315). The key eligibility criteria are as follows: 1) Histopathologically confirmed advanced solid tumor malignancy; 2) Identified HER2 amplification by Guardant360; 3) Failed prior standard therapy. The participants will receive intravenously 5.4 mg/kg of trastuzumab deruxtecan every 3 weeks. The primary endpoint is objective response rate (ORR). The planned sample size is 55-65. A Bayesian model considering the potential heterogeneity across cancer types will be applied to detect ORR of 5% versus 25% to a certain level while maintaining the false-positive error rate in each cancer type at 10%. Furthermore, tumor tissue, ctDNA and circulating tumor cells are serially collected and analyzed to investigate the predictive biomarkers and resistance mechanisms. The trial was activated in late 2019. At the time of the abstract submission, 2 patients have been enrolled. This trial is granted by AMED under Grant Number JP18lk0201084. Clinical trial information: JapicCTI-194707 .
住院老年人日常生活能力与社会支持的相关性分析
Authors: 刘学员, 廖立, 唐慧明, 李静, 赵蕾, 谭发展, 向月应
Journal: BMJ (2009)

日常生活能力是评价老年人健康状况的重要指标,社会支持影响老年人的生存质量[1],对日常生活能力与社会支持的相关性研究较少,本研究对此进行了研究,期待对提高老年人健康水平及生存质量有所裨益。
Endoscopic removal and replacement of the same lumen-apposing metal stent for multiple endoscopic necrosectomy sessions
Authors: Rishabh Gulati, Tarun Rustagi
Journal: Endoscopy (2020)

This study evaluated the feasibility, efficacy, and safety of removal and replacement of a lumen-apposing metal stent (LAMS) to facilitate direct endoscopic necrosectomy (DEN).Endoscopic ultrasound-guided LAMS placement for walled-off necrosis (WON) was performed. During subsequent endoscopy, the LAMS was removed, DEN was performed, and the same LAMS was redeployed across the transmural tract.140 LAMS were placed for drainage (43 pseudocysts, 97 WON) from 10/1/2016 to 11/15/2019, and 40 patients (mean age 43.9 [SD 15.4] years; 70 % males; mean WON size 10.9 [SD 4.9] × 8.7 [SD 3.8] cm) underwent removal and replacement of the same LAMS for multiple DEN sessions. LAMS was successfully replaced across the transmural tract during all 81 DEN sessions. Complete resolution was achieved after a median of 2 DEN sessions (range 1-7; mean 2.4 [SD 1.5]), with stent retrieval after a mean of 64.1 (SD 31.6) days after initial placement. No stent damage, tissue ingrowth, or major bleeding occurred.Removal and replacement of LAMS during multiple necrosectomies is feasible, safe, and facilitates DEN.
Real-world outcomes for neoadjuvant capecitabine versus infusional 5-fluorouracil in the treatment of locally advanced rectal cancer.
Authors: Matthew Loft, Hui-Li Wong, Suzanne Kosmider, Margaret Lee, Jeanne Tie, Rachel Wong, Ian Jones, Matthew Croxford, Malcolm Steel, Ian Faragher, Mario Guerrieri, Michael Christie, Peter Gibbs
Journal: Journal of Clinical Oncology (2020)

e16124 Background: Neoadjuvant chemoradiation therapy (CRT) is a standard of care treatment for locally advanced rectal cancer (LARC). A pathologic complete response (pCR) following CRT is an early indicator of treatment benefit and associated with excellent survival outcomes. As capecitabine replaces infusional 5-fluorouracil (5-FU) as the fluoropyrimidine of choice in routine care of LARC, on the back of clinical trial data demonstrating equivalence, it is important to confirm that efficacy is maintained in the real-world setting. Methods: We analysed data from a prospectively maintained colorectal cancer database at 3 Australian hospitals including patients diagnosed January 2009 to December 2018. Pathological response was determined as either complete or incomplete and compared for patients receiving 5FU or capecitabine. Results: 657 patients were analysed, 498 receiving infusional 5-FU and 159 capecitabine. Capecitabine use has markedly increased from approval in 2014, now being used in more than 80% of patients. Patient characteristics were similar by treatment, including age, tumour location and pre-treatment stage. pCR was reported in 22/159 (13.8%) of capecitabine treated patients and 118/380 (23.7%) that received 5-FU (p = &lt; 0.01). More capecitabine-treated patients received post-operative oxaliplatin (44.2% vs 6.3%, p &lt; 0.01). Two-year progression free survival was similar (84.9% vs 88.0%, p = 0.34). Conclusions: Capecitabine is now the dominantly used neoadjuvant chemotherapy in LARC. Capecitabine use was associated with a lower rate of pCR versus infusional 5FU, a difference not explained by examined patient or tumour characteristics. Poor treatment compliance with an oral therapy in the real-world setting is one possible explanation.
Association of Th2 high tumors with aggressive features of breast cancer.
Authors: Yoshihisa Tokumaru, Lan Le, Masanori Oshi, Eriko Katsuta, Nobuhisa Matsuhashi, Manabu Futamura, Kazuhiro Yoshida, Kazuaki Takabe
Journal: Journal of Clinical Oncology (2020)

e12584 Background: Recent studies have shown that infiltrating T-lymphocytes have been implicated in the promotion of breast cancer progression. Upon activation, these antigen-presenting cells then recruit adaptive immune cells. It has been proposed that polarization of CD4+ effector T-cells towards the immunosuppressive Th2 cells induce cytokine release and T-cell anergy, which lead to polarization of M2 tumor-associated macrophages (TAM’s), providing a protumorigenic microenvironment. We hypothesized that there is a correlation between high levels of Th2 cells and aggressive features of breast cancer and unfavorable tumor immune environment. Methods: Clinicopathological data and overall survival information was obtained on 1069 breast cancer patients from The Cancer Genome Atlas (TCGA) database. We defined Th2 high and low levels with the median cutoff. Results: Analysis of cell composition of the immune cells within tumor immune microenvironment demonstrated that Th2 high tumors did not consistently associated with unfavorable tumor immune microenvironment. Pro-cancer immune cells, such as macrophage M2 cells were increased with Th2 high tumors whereas, regulatory T cells were decreased with Th2 high tumors (p &lt; 0.01 and p &lt; 0.001 respectively). On the contrary, infiltration of anti-cancer cells, such as macrophage M1 was increased whereas CD8 T cells were decreased with Th2 high tumors (p &lt; 0.05 and p &lt; 0.001 respectively). Th2 was not shown to have correlation with IL-4, IL-6, IL-10 and IL-13, all of which has been reported to associate with Th2 cells. Th2 levels were associated with advanced grades. Also, correlation analysis demonstrated that there was a strong correlation between Th2 levels and Ki-67. These results were further validated with gene set enrichment analysis (GSEA). GSEA revealed that in Th2 high tumors enriched the gene sets associated with cell proliferation and cell cycle. Conclusions: High expression of immunosuppressive Th2 cells was associated with highly proliferative features of breast cancer, but not with unfavorable tumor immune microenvironment.
Incidence and risk factors of hypotension after spinal anesthesia induction in 1 000 patients
Authors: Feng Xu, Fayin Li, Xianlong Zhang
Journal: BMJ (2014)

The clinical parameters of 1 000 patients undergoing spinal aesthesia were recorded and analyzed.Hypotension fulfilling the predefined criteria occurred in 173 patients.The logistic regression analysis revealed that the regression coefficients of height, weight and amount of fluid infusion during anesthesia were negative while those of age, emergency operation, hypertension/hypotension, heart disease, American Society of Anesthesiologists score, use of sedative drugs and sensory blocking level of anesthesia positive.The area of receiver operating characteristic was 0.905.This study contributes to the identification of patients with high risks for hypotension after spinal induction.


Key words: 
Anesthesia, subarachnoid space; Hypotension
Clinical treatment of 100 patients with subacute thyroiditis
Authors: Shun-bin Li, Wei Qiu, Shu-ying Zheng, Wan-chun Shi
Journal: BMJ (2013)

A total of 100 patients with subacute thyroiditis hospitalized from January 2011 to October 2012 were recruited. Each received glucocorticoid treatment for 8 weeks and there was a 2-month follow-up period after drug withdrawal. After treatment, the short-term recurrence rate was 34% (34/100). If thyroid ultrasound was abnormal, the recurrence rate was 52% (30/58). And it was significantly higher than 10% recurrence rate for those with normal thyroid ultrasound (4/42, χ2=9.67, P 100 mm/1 h was 37% (22/60) and 30%(12/40) respectively (P>0.05).


Key words: 
Thyroiditis, subacute; Glucocorticoids, therapeutic uses
Activity of SY-5609, an oral, noncovalent, potent, and selective CDK7 inhibitor, in preclinical models of colorectal cancer.
Authors: Liv Johannessen, Nan Ke, Priyanka Sawant, Wojciech Dworakowski, Anthony D'Ippolito, Shanhu Hu, Nisha Rajagopal, Matthew Eaton, Graeme Hodgson
Journal: Journal of Clinical Oncology (2020)

3585 Background: Colorectal cancer (CRC) is driven by genetic alterations that result in constitutive activation of oncogenic transcription factors (eg β-catenin, MYC) and of mitogenic signaling and cell cycle progression (driven by oncogenic mutations in KRAS and BRAF). CDK7 is a key regulator of transcription, through phosphorylation of the CTD domain of RNA Polymerase II, and of cell cycle progression, through phosphorylation of the cell cycle kinases CDK1, 2, 4, and 6. This dual role of CDK7 suggests inhibitors of CDK7 may be effective in the treatment of CRC. SY-5609 is an oral, noncovalent, potent and highly selective CDK7 inhibitor in phase 1 clinical development for patients with advanced solid tumors including CRC (NCT04247126). Here we report on the activity of SY-5609 in patient-derived xenograft (PDX) models of CRC. Methods: SY-5609 was administered once daily (QD) by oral gavage for 21 days (end of treatment, EOT) to mice bearing PDX models of CRC. The relationship between SY-5609 dose, pharmacodynamic (PD) changes in xenograft tissue, tumor growth inhibition (TGI), and mouse body weight (BW) was evaluated across a range of doses. SY-5609 TGI activity was also evaluated at sub-maximum-tolerated-dose levels across a panel of 30 independent CRC models including BRAF-, KRAS-, and non-BRAF/KRAS-mutant (wild type) models (n = 10 per group). Results: SY-5609 induced dose-dependent TGI in BRAF-mutant CRC PDX tumors, with tumor regressions observed at well tolerated doses (no BW loss at EOT), and no tumor regrowth for 2+ weeks after treatment was discontinued. Dose-dependent TGI was associated with dose-dependent PD changes in PDX tumor tissue. Across 30 PDX models, SY-5609 at well-tolerated doses (average BW loss of 0% at EOT across all models) induced ≥50% TGI in 67% (20/30) of models. Deep responses (≥90% TGI or regressions) were observed in 23% (7/30) of models, with enrichment for deep responses in BRAF mutant models (50%, 5/10) relative to KRAS mutant (10%, 1/10), and wild type (10%, 1/10) models. Conclusions: Daily oral dosing of the CDK7 inhibitor SY-5609 induces robust TGI, including regressions, in CRC PDX models at well-tolerated doses. Dose-dependent TGI is associated with dose-dependent PD changes in CRC PDX tumor tissue. These results highlight the therapeutic potential of SY-5609 in CRC and support the evaluation of SY-5609 in CRC patients in early phase clinical trials. SY-5609 is in phase 1 clinical development for patients with advanced solid tumors including CRC (NCT04247126).
Community consultation and contracted management for a patient with nasosinusitis
Authors: Fuying Zhao, Yue Jiang, Cheng Yu, Xu Tian, Yue Sha
Journal: BMJ (2019)

展示社区全科医生为1例鼻窦炎患者提供连续性、专业性、超预期服务后，患者从不耐烦到遵医嘱，从拒绝到签约的过程。提示通过开放式问诊及共情回应患者的情绪，熟练运用技能为患者解决健康和疾病问题，能够帮助建立良好的医患关系，增加慢性病患者的依从性，提高患者的满意度，提升全科医生自身成就感和职业价值感。
Prevalence, risk factors and clinical outcomes of COVID-19 in patients with a history of pancreatitis in Northern California
Authors: John Gubatan, Steven Levitte, Akshar Patel, Tatiana Balabanis, Arpita Sharma, Elaina Jones, Bomi Lee, Murli Manohar, Gayathri Swaminathan, Walter Park, Aida Habtezion
Journal: Gut (2020)

<h3>Objectives</h3> To evaluate the effectiveness and cost-utility of the addition of different doses of Pilates to an advice for non-specific chronic low back pain (NSCLBP) from a societal perspective. <h3>Design</h3> Randomised controlled trial with economic evaluation. <h3>Setting</h3> Physiotherapy clinic in São Paulo, Brazil. <h3>Participants</h3> 296 patients with NSCLBP. <h3>Interventions</h3> All patients received advice and were randomly allocated to four groups (n=74 per group): booklet group (BG), Pilates once a week (Pilates group 1, PG1), Pilates twice a week (Pilates group 2, PG2) and Pilates three times a week (Pilates group 3, PG3). <h3>Main outcome measures</h3> Primary outcomes were pain and disability at 6-week follow-up. <h3>Results</h3> Compared with the BG, all Pilates groups showed significant improvements in pain (PG1, mean difference (MD)=−1.2, 95% CI −2.2 to −0.3; PG2, MD=−2.3, 95% CI −3.2 to −1.4; PG3, MD=−2.1, 95% CI −3.0 to −1.1) and disability (PG1, MD=−1.9, 95% CI −3.6 to −0.1; PG2, MD=−4.7, 95% CI −6.4 to −3.0; PG3, MD=−3.3, 95% CI −5.0 to −1.6). Among the different doses, PG2 showed significant improvements in comparison with PG1 for pain (MD=−1.1, 95% CI −2.0 to −0.1) and disability (MD=−2.8, 95% CI −4.5 to −1.1). The cost-utility analysis showed that PG3 had a 0.78 probability of being cost-effective at a willingness-to-pay of £20 000 per quality-adjusted life-year gained. <h3>Conclusions</h3> Adding two sessions of Pilates exercises to advice provided better outcomes in pain and disability than advice alone for patients with NSCLBP; non-specific elements such as greater attention or expectation might be part of this effect. The cost-utility analysis showed that Pilates three times a week was the preferred option. <h3>Trial registration number</h3> NCT02241538, Completed.
“Social physiology” for psychiatric semiology: How TTOM can initiate an interactive turn for computational psychiatry?
Authors: Guillaume Dumas, Tudi Gozé, Jean-Arthur Micoulaud-Franchi
Journal: Behavioral and Brain Sciences (2020)

Abstract Thinking through other minds (TTOM) encompasses new dimensions in computational psychiatry: social interaction and mutual sense-making. It questions the nature of psychiatric manifestations (semiology) in light of recent data on social interaction in neuroscience. We propose the concept of “social physiology” in response to the call by the conceivers of TTOM for the renewal of computational psychiatry.
Management of medical inoperable and tyrosine kinase inhibitor-naive early-stage lung adenocarcinoma with epidermal growth factor receptor mutations: A retrospective multi-institutional analysis.
Authors: Yue Mei Sun, Ming Xiu Zhou, Ming Zeng
Journal: Journal of Clinical Oncology (2020)

e21082 Background: The clinical value of combined local radiation and epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) and for medical inoperable and TKI-naïve early-stage lung adenocarcinoma patients with EGFR mutations is not yet determined. In this study, we aimed to pool multi-institutional data to compare the therapeutic effect of EGFR-TKI alone and combined radiation and TKI on the survival outcomes in this patient subgroup. Methods: 132 cases of medical non-operable stage I to III EGFR mutant lung adenocarcinoma were retrospectively reviewed based on data from 5 centers. Among the patients, 65 cases received combined radiation and EGFR-TKI therapy (R+TKI) (49.2%), while 67 cases had EGFR-TKI (50.8%) treatment alone. All patients were followed until death. Results: For R+TKI group, the median overall survival (OS) after primary therapy was 42.6 months, while that of the TKI alone group was 29.4 months (log-rank p &lt; .001). In terms of progression-free survival (PFS), the median PFS in these two treatment groups were 24 months and 14.7 months respectively (log-rank p &lt; .001). Multivariate analysis showed that R+TKI was independently associated with improved OS (adjusted HR: 0.420; 95% CI, 0.287 to 0.614; p &lt; .001) and PFS (adjusted HR: 0.420; 95% CI, 0.291 to 0.605; p &lt; .001) compared to TKI alone. Subgroup analysis confirmed the significant OS benefits in stage III patients and RFS benefits in stage II/III patients. Conclusions: Upfront radiation to primary sites with TKI to follow was a feasible option for patients with EGFR-mutant medical inoperable non-small-cell lung carcinoma (NSCLC) during first-line EGFR-TKI treatment, with significantly improved PFS and OS compared with TKI alone
由长阳土家族自治县看农村的合作医疗问题
Authors: 匡建华
Journal: BMJ (2006)

在社会发展进程中,农村合作医疗进行了长期艰苦且有益地探索.新型农村合作医疗的实施虽然巩固了合作医疗的发展成果,但在政策、资金筹集和运行等诸多方面仍还不够完善,有待进一步分析并研究对策。
Reply to Tuffet <i>et al.</i> and to Michard and Shelley
Authors: Roberto Tonelli, Luca Tabbì, Riccardo Fantini, Ivana Castaniere, Filippo Gozzi, Stefano Busani, Stefano Nava, Enrico Clini, Alessandro Marchioni
Journal: American Journal of Respiratory and Critical Care Medicine (2020)
Implementation of contracted family doctor services model in Changning district of Shanghai
Authors: Ping Jiang, Lei Xu, Qi Zhao, Qiong Wu, Minjie Zhu, Biao Xu
Journal: BMJ (2016)

2011年起上海市长宁区对社区家庭医生签约服务工作进行了有序探索，已形成了家庭医生签约、居民社区首诊、政策支持到位、薪酬绩效考核的良性循环局面。通过对其家庭医生签约服务的做法、签约服务内容要求与绩效考核和服务成效进行总结探讨，旨在为社区家庭医生签约服务提供参考，并提出优化服务内容、提升服务内涵、完善服务体系是社区家庭医生签约服务制下一步发展的重点。